MedTrace Logo

A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19

NCT04621903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-11-19

No results posted yet for this study

Summary

The COVID-19 pandemic is considered as the most crucial global health concern of the century. Given the complex interaction of physical and social factors on fast spreading infection, there have been increasing calls for comprehensive efforts using a community-based participatory research (CBPR) approach.

CBPR partnership composed of representatives from community-based organisations, health and academia actively developed the present study. Specific aims were (1) to assess the efficacy and safety of Ayurvedic combination, Giloy (Tinospora Cordifolia) and Pippali (Piper longum) in the management of mild-to-moderate cases of COVID-19 and (2) to determine the effect in relieving COVID-19 symptoms and preventing the onset of severe infection.

Conditions

  • Covid19

Interventions

OTHER

Shanshamani Vati Plus

Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.

Sponsors & Collaborators

  • University of Warwick

    collaborator OTHER

  • All India Institute of Ayurveda, Ministry of AYUSH, Government of India

    collaborator UNKNOWN

  • Aarogyam UK

    lead OTHER

Principal Investigators

  • Vishwesh Kulkarni · University of Warwick

  • Neha Sharma · Aarogyam UK

  • Dipa Modi · East Park Medical Centre, Leicester NHS Trust

  • Tanuja Nesari · All India Institute of Ayurveda, Ministry of AYUSH, Government of India

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-08
Primary Completion
2020-10-27
Completion
2020-11-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621903 on ClinicalTrials.gov